n the latest move by a country to crack down on anti-competitive behavior by drug makers, Ukrainian regulators fined Sanofi (SNY) approximately $2.6 million for purportedly working with two distributors to restrict competition of dozens of medicines several years ago.

In a decision issued on Tuesday, the Antimonopoly Committee explained that, during 2010 and 2011, the drug maker provided unspecified “conditions and discounts” to the distributors — BadMM and Optimum-Farm — to market Sanofi medicines for which lower-cost generic competition existed.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.